Delivers expanded heme-onc menu and the ability to analyze low-input samples
SOUTH SAN FRANCISCO — Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced two key improvements to the core capabilities of its Tapestri Platform intended to expand its accessibility and utility in the area of hematologic oncology (heme-onc) research. These new additions to Tapestri will enable researchers to apply single-cell analysis in a wider range of projects than previously possible through the introduction of new ready-to-use panels and a lowered input threshold.
With Tapestri’s expanded capabilities, heme-onc researchers can now access single-cell insights from as few as 20,000 cells while conserving precious samples. Mission Bio is also launching Tapestri Single-cell DNA Published Panels, a new set of pre-designed gene panels sourced from leading investigators in the field covering various indications. These newly available gene panels have powered discoveries across hematological malignancies including acute lymphoblastic leukemia (ALL), and have been featured and verified in peer-reviewed publications like Blood.
“We are excited to include our ALL panel with the initial launch of Tapestri Single-cell DNA Published Panels,” said Jan Cools, PhD, Group Leader at VIB, Center for Cancer Biology. “We developed this panel as a sensitive assay to detect clonal architecture and evolution in T-cell ALL, the basis for our study on T-cell ALL published in Blood. We hope the availability of these panels can accelerate single-cell studies for those new to Tapestri.”
Another key addition to Tapestri for simultaneous single-cell DNA and protein analysis is BioLegend’s expanded TotalSeq™-D antibodies catalog. Taking these advances together, researchers can now start with a pre-designed heme-oncology panel or customize one to fit the needs of a specific project, connect genomic data to a broader array of phenotypes, and do it all in a smaller sample.
“Researchers have been using the Tapestri Platform to make strides in hematologic oncology research, with breakthrough applications in therapy resistance and measurable residual disease,” said Yan Zhang, CEO of Mission Bio. “We are thrilled to lower the barrier to entry with a lower input threshold and expanded menu of ready-to-use panels and antibodies that will more easily enable single-cell multi-omics insights and advance critical research.”
In addition to customers presenting Tapestri data this week at the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, Mission Bio will be hosting a virtual launch event on Tuesday, Sept. 21 at 8 a.m. PT/11 a.m. ET. To register for the event, please visit the registration page.
About Mission Bio
Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range of diseases by equipping researchers with the tools they need to better measure and predict our resistance and response to new therapies. Mission Bio’s multi-omics approach improves time-to-market for new therapeutics, including innovative cell and gene therapies that provide new pathways to health. Founded in 2014, Mission Bio has secured investment from Novo Growth, Cota Capital, Agilent Technologies, Mayfield Fund, and others.
The company’s Tapestri platform gives researchers around the globe the power to interrogate every molecule in a cell together, providing a comprehensive understanding of activity from a single sample. Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously from the same sample at single-cell resolution. The Tapestri Platform is being utilized by customers at leading research centers, pharmaceutical, and diagnostics companies worldwide to develop treatments and eventually cures for cancer. To learn more, visit missionbio.com.